The lack of access to health services and the inability to acquire the needed drugs is one of the main problems in the healthcare sector of the USA. The existence of the given issue preconditions the deterioration of the health of the nation and poor outcomes among vulnerable populations. For this reason, it is possible to justify the proposed policy and admit the need for changes in the existing legal field to guarantee the increased affordability of prescription drugs for clients who have special requirements (“H.R.7348 – Affordable Drug Manufacturing Act of 2018,” n.d.). The systematic change in the regulations is one of the most effective ways to guarantee improvements in healthcare as it means the governmental support of proposed incentives, which is the key to future achievements and the ability to drive positive change.
The evidence proposed to support the health policy also seems reliable and credible. The broad category of Americans (20% of all population) faces the high risk of acquiring multiple complications because of their inability to afford the demanded care and medications (Zarei et al., 2020). Additionally, statistics show that 58 million also suffer from the given problem because of the problems with prescription drugs (Lockwood, 2019). For this reason, the introduction of the proposed health policy becomes vital for achieving the goal of promoting the health of the nation and transforming the healthcare sector to make health services more affordable to people. Regarding the provided evidence and the arguments, the proposed health policy can be viewed as an appropriate step needed to balance the healthcare service and avoid discrepancies between the provision and distribution of services. At the same time, the increased affordability of prescription drugs might demand additional change in diagnosing and examining patients to avoid problems with mistreatment.
References
H.R.7348 – Affordable Drug Manufacturing Act of 2018. (n.d.). Web.
Lockwood, C. (2019). Ensuring medications are more affordable without stifling innovation (Part 2): In the second part of this series, potential solutions to fix the rising drug cost problem are examined. Contemporary OB/GYN, 64(7), 3–6.
Zarei, L., Karimzadeh, I., Moradi, N., Peymani, P., Asadi, S., & Babar, Z. (2020). Affordability assessment from a static to dynamic concept: A scenario-based assessment of cardiovascular medicines. International Journal of Environmental Research and Public Health, 17(5), 1710. Web.